Communiqués S2Medical AB

Actions

S2M

SE0011725084

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 19/06/2024			Varia. 5j.	Varia. 1 janv.
0,036 ^SEK	-7,69%		0,00%	-40,00%

17/05	S2Medical AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
20/02	S2Medical AB (publ) annonce ses résultats pour le quatrième trimestre clos le 31 décembre 2023	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

S2Medical AB (publ) Signs Exclusive Distribution Agreement with Provas Medical Ltd for the Turkish Market	06/11	AQ
INTERIM REPORT APRIL - JUNE 2023	25/08/23	AQ
S2Medical AB (publ) announces final outcome in the company's rights issue	05/07/23	AQ
S2Medical AB Secures New Loan Agreement and Aims to be Debt-Free by July 2024	04/07/23	AQ
S2Medical (publ) announces preliminary outcome in the company's rights issue	03/07/23	AQ
S2Medical AB (publ) publishes a prospectus regarding the rights issue	16/06/23	AQ
S2Medical AB (publ) signs a manufacturing agreement with a distributor in Saudi Arabia	08/06/23	AQ
S2Medical AB (publ) signs a distribution agreement for the Iranian market	17/05/23	AQ
S2Medical wins procurement for wound healing items in the Västra Götaland region	16/05/23	AQ
Postponing of publication of the quarterly report for the period January to March 2023	10/05/23	AQ
Postponement of publication of annual report	24/04/23	AQ
S2Medical wins procurement for wound healing items in the United Arab Emirates worth approximately SEK 3.4 million	21/04/23	AQ
S2Medical AB (publ) signs a distributor agreement in the United Arab Emirates and delivers a record order of the skin substitute Epiprotect worth about SEK 2 million	13/04/23	AQ
S2Medical implements a strategic change to reach profitability faster	28/03/23	AQ
S2Medical wins procurement for wound healing equipment in Region Halland	03/03/23	AQ
Year-end report January - December 2022 S2Medical AB (publ)	22/02/23	AQ
Postponing of publication of the year-end report	16/02/23	AQ
Positive outcome when S2Medicals antimicrobial peptides were tested against the multi resistant bacteria that by WHO have been defined as a global health threat	02/01/23	AQ
Epiprotect reduces the cost for treatment of hard to heal leg ulcers with 83%	02/12/22	AQ
INTERIM REPORT JULY-SEPTEMBER 2022	11/11/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués S2Medical AB

Actions

S2M

SE0011725084

Communiqués

Filtres